标题/作者	年份
Integrating evolutionary dynamics into cancer therapy RA Gatenby, JS Brown Nature reviews Clinical oncology 17 (11), 675-686	2020
Multiple myeloma: Role of autologous transplantation I Ntanasis-Stathopoulos, M Gavriatopoulou, E Kastritis, E Terpos, ... Cancer treatment reviews 82, 101929	2020
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma T Facon, CP Venner, NJ Bahlis, F Offner, DJ White, L Karlin, ... Blood, The Journal of the American Society of Hematology 137 (26), 3616-3628	2021
Melflufen: a peptide–drug conjugate for the treatment of multiple myeloma MV Mateos, J Bladé, S Bringhen, EM Ocio, Y Efebera, L Pour, F Gay, ... Journal of clinical medicine 9 (10), 3120	2020
Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches IV Kostopoulos, I Ntanasis-Stathopoulos, M Gavriatopoulou, ... Frontiers in oncology 10, 860	2020
Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma SF Cho, L Xing, KC Anderson, YT Tai Cancers 13 (23), 6136	2021
Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects G Lassiter, C Bergeron, R Guedry, J Cucarola, AM Kaye, EM Cornett, ... Current Oncology 28 (1), 640-660	2021
Overcoming the immunosuppressive tumor microenvironment in multiple myeloma FM Uckun Cancers 13 (9), 2018	2021
Treatment of multiple myeloma and the role of melphalan in the era of modern therapies—Current research and clinical approaches A Poczta, A Rogalska, A Marczak Journal of Clinical Medicine 10 (9), 1841	2021
Gut microbiota influence in hematological malignancies: From genesis to cure M Uribe-Herranz, N Klein-González, LG Rodríguez-Lobato, M Juan, ... International Journal of Molecular Sciences 22 (3), 1026	2021
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma H Nahi, M Chrobok, S Meinke, C Gran, N Marquardt, G Afram, T Sutlu, ... Cell Reports Medicine 3 (2)	2022
Staging system to predict the risk of relapse in multiple myeloma patients undergoing autologous stem cell transplantation C Goswami, S Poonia, L Kumar, D Sengupta Frontiers in oncology 9, 633	2019
Mathematical models of cancer and different therapies R Padmanabhan, N Meskin, AE Al Moustafa Springer	2021
Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study BA Zannetti, F Saraceni, C Cellini, E Fabbri, F Monaco, A Guarini, ... Transplantation and cellular therapy 27 (3), 244. e1-244. e8	2021
Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma J Ackley, MA Ochoa, D Ghoshal, K Roy, S Lonial, LH Boise Cancers 13 (19), 4787	2021
Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma is Ready for Primetime D Kazandjian, O Landgren Clinical advances in hematology & oncology: H&O 17 (10), 559	2019
The effect of marital status on the survival of patients with multiple myeloma L Tang, Z Pan, X Zhang Hematology 27 (1), 187-197	2022
CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival inmultiple myeloma patients undergoing autologous stem cell transplantation EA Karakulak, H Demiroğlu, Y Büyükaşik, M Turgut, S Aksu, N Sayinalp, ... Turkish journal of medical sciences 50 (8), 1851-1856	2020
Bispecific antibodies in multiple myeloma treatment: a journey in progress SF Cho, TJ Yeh, KC Anderson, YT Tai Frontiers in Oncology 12, 1032775	2022
Boosting immunity against multiple myeloma R Lopes, BV Ferreira, J Caetano, F Barahona, EA Carneiro, C João Cancers 13 (6), 1221	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。